5VM
ELVN icon

5AM Venture Management’s Enliven Therapeutics ELVN Stock Holding History

5AM Venture Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-772,477
Closed -$11.9M – 21
2025
Q4 		$11.9M Hold
772,477
– – 3.74% 12
2025
Q3 		$15.8M Hold
772,477
– – 5.79% 7
2025
Q2 		$15.5M Sell
772,477
-550,000
-42% -$10.4M 5.96% 4
2025
Q1 		$26M Sell
1,322,477
-307,288
-19% -$6.61M 9.84% 2
2024
Q4 		$36.7M Sell
1,629,765
-122,409
-7% -$3.17M 8.75% 2
2024
Q3 		$44.8M Sell
1,752,174
-858,701
-33% -$19.9M 9.25% 2
2024
Q2 		$61M Sell
2,610,875
-1,225,100
-32% -$25.8M 13.65% 3
2024
Q1 		$67.5M Sell
3,835,975
-1,325,000
-26% -$20.3M 15.11% 1
2023
Q4 		$71.4M Hold
5,160,975
– – 18.95% 1
2023
Q3 		$70.5M Sell
5,160,975
-637,500
-11% -$10.7M 20.29% 1
2023
Q2 		$118M Hold
5,798,475
– – 29.48% 1
2023
Q1 		$127M Buy
+5,798,475
New +$118M 32.47% 1

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

5AM Venture Management's ELVN Position: Q1 2026 in Review

5AM Venture Management sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 772,477 shares — an estimated $11.9M sold.

5AM Venture Management first reported a position in ELVN in Q1 2023 and held it in 12 quarters. The position peaked at $127M in Q1 2023. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • 5AM Venture Management reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • 5AM Venture Management sold 772,477 Enliven Therapeutics shares in Q1 2026, an estimated $11.9M.
  • 5AM Venture Management first reported a position in Enliven Therapeutics in Q1 2023 and held it in 12 quarters.
  • 5AM Venture Management's Enliven Therapeutics position peaked at $127M in Q1 2023.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.